02 03 Inside HSCA: HSCA Announces Support for Legislation to Help Address Generic Drug Price Spikes 04 05 15 16 19 20 21 22 23 24 25 26 27 28 31 32 33

HSCA Announces Support for Legislation to Help Address Generic Drug Price Spikes

34
The Healthcare Supply Chain Association (HSCA) today announced its support for the “Increasing Competition in Pharmaceuticals Act” (S.2615), new legislation from Senators Susan Collins (R-ME) and Claire McCaskill (D-MO) aimed at creating a more competitive generic drug marketplace.

 “The Increasing Competition in Pharmaceuticals Act (S.2615) is an important step toward fostering a more competitive generic drug marketplace and ensuring patient access to affordable medications,” said HSCA President and CEO Todd Ebert, R.Ph. “HSCA applauds Senators Collins and McCaskill for their leadership on S.2615 and we support the legislation’s mandated priority review of abbreviated new drug applications (ANDAs) for generic drugs made by just one manufacturer. Healthcare group purchasing organizations have a unique line of sight on the healthcare supply chain, and we look forward to continuing to serve as a resource to the Senate Special Committee on Aging as they work to advance S.2615.”

HSCA confirmed its support for the “Increasing Competition in Pharmaceuticals Act” in a letter to the Chair and Ranking Member of the Senate Special Committee on Aging, which also thanked the Senators for their ongoing work to reduce healthcare costs and safeguard patient and provider access to generic drugs. The letter went on to encourage the Committee to consider future enhancements to the legislation, in the form of a new subsection that also mandates priority review for generic injectable drugs with two or fewer manufacturers.

To read the full letter, click here


To read the full release, click here.
35 36 37 38